课题基金 / 基金详情

Neuroprotective Roles for Neuregulins in Neurotoxin-mediated Neuronal Injury

Neuroprotective Roles for Neuregulins in Neurotoxin-mediated Neuronal Injury
神经调节蛋白在神经毒素介导的神经元损伤中的神经保护作用
批准号:
7225102
负责人:
BYRON D. FORD
金额:
$67.23万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-27 至 2011-05-31

项目摘要

项目成果

BYRON D. FORD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Organophosphorus nerve agents (OP) are toxic chemicals that have been used by terrorists in military combat and against civilian populations. Current clinical post-exposure countermeasures against OP nerve agents are useful in preventing mortality, but are not sufficiently effective in protecting the CMS from seizures and permanent injury. Therefore, new and more effective countermeasures against chemical threats must be developed to facilitate better medical treatment of civilians and military personnel following exposure to OP. Recent studies have demonstrated the existence of neuronal injury, secondary to the stimulation of cholinergic pathways, which is associated with pro-inflammatory processes in the CMS during exposure to the nerve agents. The use of anti-inflammatory compounds, in combination with the current antidotal drugs, has been shown to decrease toxic symptoms and inflammation-induced brain damage. The objective of this study was to evaluate the therapeutic benefit of administration of neuregulin-1 (NRG-1), a neuroprotective, anti-inflammatory compound, alone or as a complement to the standard therapy against OP nerve agent poisoning. Recent work from our lab demonstrated NRG-1 reduced neuronal death in a rat focal ischemia model. The central hypothesis of this project is that NRG-1, alone or in combination with classical antidotal drugs, represents a novel, enhanced neuroprotective strategy that prevents non-AChE-mediated neuronal injury following exposure to OP with an extended therapeutic window. To test our hypothesis, we will employ the following set of specific aims: (1) To determine the prophylactic neuroprotective capacity of NRG-1 in OP-mediated neuronal injury; (2) To investigate whether co-administration of NRG-1 with classical antidotal drugs enhances neuroprotection from OP-mediated injury ; (3) To determine the post-exposure therapeutic window for NRG-1 in neuroprotection from OP-mediated injury and (4) To determine the feasibility of using in vitro models for screening neuregulin combinatorial therapies for neuroprotection against OP-induced neuronal injury. As a potential counterterrorism agent, NRG-1 represents a promising adjuvant therapy to the currently available antidotal treatments to ensure optimal treatment of OP nerve agent poisoning in humans. Therefore, NRG-1 represents a novel, potent neuroprotective strategy that has potential therapeutic value in treating individuals after acute exposure to neurotoxic compounds.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protective role of Neuregulin-1 against cerebral malaria-induced neuronal injury and behavioral sequelae
  • 批准号:
    10541866
  • 项目类别:
  • 资助金额:
    $54.22万
  • 财政年份:
    2022
  • 负责人:
    BYRON D. FORD
  • 依托单位:
Protective role of Neuregulin-1 against cerebral malaria-induced neuronal injury and behavioral sequelae
  • 批准号:
    10391193
  • 项目类别:
  • 资助金额:
    $55.78万
  • 财政年份:
    2022
  • 负责人:
    BYRON D. FORD
  • 依托单位:
Device for Improving Outcomes Following Decompressive Hemicraniectomy for Stroke
Riverside Bridges to the Baccalaureate Program (Riverside B2B)
国内基金
海外基金
脐带间充质干细胞微囊联合低能量冲击波治疗神经损伤性ED的机制研究
  • 批准号:
    82371631
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    卢慕峻
  • 依托单位:
α-酮戊二酸调控ACMSD介导犬尿氨酸通路代谢重编程在年龄相关性听力损失中的作用及机制研究
  • 批准号:
    82371150
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    侯书乐
  • 依托单位:
基于再生运动神经路径优化Agrin作用促进损伤神经靶向投射的功能研究
  • 批准号:
    82371373
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    沃雁
  • 依托单位:
NPM1表观重塑巨噬细胞代谢及修复表型在心肌缺血损伤中的调控作用
  • 批准号:
    82371825
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    占贞贞
  • 依托单位: